Trial Profile
A Phase 1/2a trial of Proxinium in combination with a checkpoint inhibitor for the treatment of late-stage squamous cell carcinoma of the head and neck
Status:
Planning
Phase of Trial:
Phase I/II
Latest Information Update: 30 Mar 2023
Price :
$35
*
At a glance
- Drugs Oportuzumab monatox (Primary)
- Indications Head and neck cancer
- Focus Therapeutic Use
- 07 Mar 2023 According to a Carisma Therapeutics media release, Carisma Therapeutics merged with the Sesen Bio. The combined companies are named as Carisma Therapeutics.
- 16 May 2018 According to a Sesen Bio media release, Eleven Biotherapeutics changed its name to Sesen Bio.
- 24 Mar 2017 According to an Eleven Biotherapeutics media release, company anticipates initiating this trial in the second half of 2017.